Clinical Trial Update: Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100) [Phase 2]

View source ↗

Summary

Phase 2 rollover study update for Vicriviroc (SCH 417690) in HIV-infected participants; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Vicriviroc (MK-7690)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV, HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2020-12-03